ClinicalTrials.gg
RecruitingNCT06681129NiiCEUpdated Mar 27, 2026

Study of Normal Intestinal Development and Disease in Premature and Term Neonates

An observational study in NEC, Necrotizing Enterocolitis and Intestinal Disease, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Boston Children's Hospital · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
Up to 2 Years
Sex
All
01

Study summary

Current research on early intestinal development is primarily performed in mouse models. While useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs between the two species. Further, prior research has demonstrated that some proteins and pathways that are critical in human development have no clear role in mice.

This study aims to improve the overall understanding of critical aspects of intestinal development in humans. In addition, this study will investigate the impact of intestinal diseases that are found in the early stages of life such as necrotizing enterocolitis (NEC).

02

Conditions studied

  • NEC
  • Necrotizing Enterocolitis
  • Intestinal Disease
  • Human Development

Keywords

  • NEC
  • Early Intestinal Development
  • Intestinal Intervention
  • Necrotizing Enterocolitis
03

In context

Enterocolitis, Necrotizing

228 studies on the registry are indexed under Enterocolitis, Necrotizing; 44 are open to participants now.

This study's planned enrollment of 100 is below the median of 144 across 95 observational studies indexed under Enterocolitis, Necrotizing.

Browse Enterocolitis, Necrotizing studies →

Lead sponsor

Boston Children's Hospital is the lead sponsor of 608 studies on the registry; 147 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Neonates or infants that are admitted to the in-patient units for intestinal intervention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any neonate or infant through 2 years of age having intestinal surgery or intestinal from an esophogastroduodenoscopy (EGD) or colonoscopy.

Exclusion criteria

Exclusion Criteria:

  • Children > 2 years of age.
  • Infants 0-2 years old not undergoing GI surgery or intestinal scope with procedure.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Neonates

    Any neonate or infant up to 2 years of age scheduled for an intestinal surgery or an esophogastroduodenoscopy or colonoscopy.

06

What researchers measure

Primary outcomes

  1. Number of intestinal stem cells and mature epithelial cells

    Small intestinal biopsy specimens will be collected either from discarded surgical biopsies collected for clinical reasons or from 1-2 additional small bunch biopsies (5mm) near the surgery site. The tissue will be used to 1.) generate organoids for longitudinal cell culture, 2.) analyze RNA or protein components by transcriptomic or cellular analyses or 3.) analyze histology. We do not have discrete planned outcomes because this is an investigational study and we are looking for new trends or differences.

    Time frame: At the time of surgery for another clinical problem.

  2. Degree of Immune System Changes

    We will collect a small 1 tsp amount of blood (5mL) and use this to analyze immune cell types or cytokines in the blood. These will include monocytes, T cell, B cells, and neutrophils for the cell types. Cytokines will include IL-1, IL-2, IL-3, IL-4, Il-5, IL-6, Il-8, IL10, IL-13, IL-22, IL-33, TNFa, IFNg, IFNa, MCP1, MIP1a.

    Time frame: Within 48 hours before or after the clinically-driven surgery.

  3. Fraction of Stool Microbiome that has beneficial microbes

    We will collect stool samples to analyze the microbiome using bulk microbial RNA sequencing.

    Time frame: Within 48 hours before or after the surgery from which the biopsy is obtained.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681129
Responsible party
Amy O'Connell (Physician in Medicine, Division of Newborn Medicine; Director of Infection Control, Neonatal ICU; Faculty, Neonatal Genomics Program, Boston Children's Hospital) — Principal investigator
First posted
Nov 8, 2024
Start date
Mar 17, 2025
Primary completion
Sep 1, 2031 (estimated)
Completion
Dec 31, 2034 (estimated)
Last update
Mar 27, 2026

Study contacts

Amy O'Connell, MD, PhD
Contact
Amy.OConnell@childrens.harvard.edu
617-919-1807
Kate Eident, BS
Contact
katherine.eident@childrens.harvard.edu
617-355-2184
Amy O'Connell, MD, PhD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion